News
ADPT
--
0.00%
--
Chief Scientific Officer Of Adaptive Biotechnologies Trades $505.90 Thousand In Company Stock
Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies (NASDAQ:ADPT), made a large buy and sell of company shares on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission r...
Benzinga · 3d ago
BRIEF-Adaptive Biotechnologies To Present New Sars-Cov-2 Data From Its Immune Medicine Platform During IDweek 2021
reuters.com · 3d ago
Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021
Research demonstrates the ability of Adaptive’s immune medicine platform to distinguish natural infection from vaccine response and the ability to detect prior infection nearly 12 months after initial diagnosis in some patientsSEATTLE, Sept. 16, 2021 (GLOB...
GlobeNewswire · 3d ago
Adaptive Biotechnologies Insider Trades $1.67 Million In Company Stock
Chad Robins, CEO And Chairman at Adaptive Biotechnologies (NASDAQ:ADPT), made a large insider sell on September 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Robins ...
Benzinga · 6d ago
Adaptive Biotechnologies Corp (ADPT) CEO and Chairman Chad M Robins Sold $1.7 million of Shares
GuruFocus News · 09/11 12:15
Adaptive Biotechnologies Corp (ADPT) CFO Chad M Cohen Sold $567,381 of Shares
GuruFocus News · 09/10 12:15
Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating vi...
GlobeNewswire · 09/07 21:15
3 Stocks in Cathie Wood�s ARK Genomic Revolution Fund that Wall Street Loves
StockNews.com · 09/07 13:05
Invesco Main Street Small Cap Fund Buys Heska Corp, The Honest Co Inc, Amyris Inc, Sells ...
GuruFocus News · 09/01 18:38
Casdin Capital, LLC Buys Verve Therapeutics Inc, Century Therapeutics Inc, Singular Genomics ...
GuruFocus News · 08/24 14:38
SB Management Ltd Buys Century Therapeutics Inc, Lyell Immunopharma Inc, ironSource, Sells ...
GuruFocus News · 08/23 21:38
Aristotle Atlantic Partners, LLC Buys Vertex Pharmaceuticals Inc, Snowflake Inc, Adaptive ...
GuruFocus News · 08/18 19:38
Adaptive Biotechnologies Corp (ADPT) CFO Chad M Cohen Sold $511,050 of Shares
GuruFocus News · 08/13 16:15
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 08/12 05:19
Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access
and , /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, and Adaptive Biotechnologies Corp. (Nasdaq: ADPT), a biotechnology company that aims to translate the genetics of the adaptive immune system into clinical pro...
PR Newswire - PRF · 08/10 18:12
Andreas Halvorsen Gets a Healthy Dose of Rallybio
GuruFocus News · 08/10 14:44
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 18.60% and 20.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 22:25
BRIEF-Adaptive Biotechnologies Reports Q2 2021 Financial Results
reuters.com · 08/04 21:44
BRIEF-Adaptive Biotechnologies Appoints Nitin Sood As Chief Commercial Officer
reuters.com · 08/04 21:44
Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin S...
GlobeNewswire · 08/04 20:15
Webull provides a variety of real-time ADPT stock news. You can receive the latest news about Adaptive Biotechnologies through multiple platforms. This information may help you make smarter investment decisions.
About ADPT
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.